Guggenheim analyst Yatin Suneja upgraded Immunovant to Buy from Neutral with a $30 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMVT:
- Immunovant price target raised to $21 from $17 at H.C. Wainwright
- Immunovant price target raised to $21 from $19 at Chardan
- Immunovant expects cash to fund operations into 2H25
- Immunovant decides not to pursue WAIHA indication for batoclimab
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022